UK markets closed

Freeline Therapeutics Holdings plc (FRLN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.5990-0.0210 (-3.39%)
At close: 03:23PM EST
0.6299 +0.01 (+1.60%)
After hours: 04:06PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 40.28M
Enterprise value -13.60M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.59
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.13

Trading information

Stock price history

Beta (5Y monthly) 0.18
52-week change 3-73.04%
S&P500 52-week change 3-11.32%
52-week high 32.6380
52-week low 30.5800
50-day moving average 30.6860
200-day moving average 30.8542

Share statistics

Avg vol (3-month) 323.59k
Avg vol (10-day) 314.3k
Shares outstanding 564.97M
Implied shares outstanding 6N/A
Float 817.61M
% held by insiders 10.00%
% held by institutions 158.49%
Shares short (14 Nov 2022) 4133.54k
Short ratio (14 Nov 2022) 47.41
Short % of float (14 Nov 2022) 4N/A
Short % of shares outstanding (14 Nov 2022) 40.21%
Shares short (prior month 13 Oct 2022) 4136.84k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-50.15%
Return on equity (ttm)-90.95%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -106.63M
Net income avi to common (ttm)-100.67M
Diluted EPS (ttm)-3.5290
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)65.85M
Total cash per share (mrq)1.01
Total debt (mrq)11.96M
Total debt/equity (mrq)17.44
Current ratio (mrq)3.31
Book value per share (mrq)1.06

Cash flow statement

Operating cash flow (ttm)-75.66M
Levered free cash flow (ttm)-48.27M